Titre : Review - HCC Risk and Direct-Acting Antivirals
link : Review - HCC Risk and Direct-Acting Antivirals
Review - HCC Risk and Direct-Acting Antivirals
Medscape Coverage from
Digestive Disease Week (DDW) 2017
COMMENTARY
With Hepatitis C Virus on the Run, Meet the New Challenge: Hepatocellular Carcinoma
William F. Balistreri
July 26, 2017
Digestive Disease Week (DDW) 2017
COMMENTARY
With Hepatitis C Virus on the Run, Meet the New Challenge: Hepatocellular Carcinoma
William F. Balistreri
July 26, 2017
Significant advances in the clinical practice of hepatology were addressed during this year's Digestive Disease Week. This review focuses on the concerns related to the apparent increase in the incidence of hepatocellular carcinoma (HCC).
HCC Risk and Direct-Acting Antivirals
The advent of direct-acting antivirals (DAAs) has clearly brought good news, as it may now be possible to achieve a sustained virologic response (SVR)—a "virologic cure"—in the majority of patients with chronic hepatitis C virus (HCV). However, emerging data suggest that the risk for HCC may persist or even be increased by DAA administration. This concern was addressed by two studies
Continue reading....
Free registration may be required
On This Blog
Liver Cancer After Treatment For Hepatitis C
Sift through a collection of current articles investigating the possible risk of developing liver cancer (hepatocellular carcinoma, or HCC) during and after direct-acting antiviral therapy in patients with hepatitis C.
HCC Risk and Direct-Acting Antivirals
The advent of direct-acting antivirals (DAAs) has clearly brought good news, as it may now be possible to achieve a sustained virologic response (SVR)—a "virologic cure"—in the majority of patients with chronic hepatitis C virus (HCV). However, emerging data suggest that the risk for HCC may persist or even be increased by DAA administration. This concern was addressed by two studies
Continue reading....
Free registration may be required
On This Blog
Liver Cancer After Treatment For Hepatitis C
Sift through a collection of current articles investigating the possible risk of developing liver cancer (hepatocellular carcinoma, or HCC) during and after direct-acting antiviral therapy in patients with hepatitis C.
Thus articles Review - HCC Risk and Direct-Acting Antivirals
that is all articles Review - HCC Risk and Direct-Acting Antivirals This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Review - HCC Risk and Direct-Acting Antivirals the link address https://newsaninpiration.blogspot.com/2017/07/review-hcc-risk-and-direct-acting.html
0 Response to "Review - HCC Risk and Direct-Acting Antivirals"
Post a Comment